Controlled Study to Evaluate the Safety and Efficacy of the Predictix Antidepressant Clinician Support Tool

A Prospective, Randomized, Controlled Study to Evaluate the Safety and Efficacy of the Predictix Antidepressant Clinician Support Tool in Prescribing Antidepressant Medication for the Treatment of Patients Diagnosed With Major Depressive Disorder

The study will compare two groups of patients: a control group of patients treated per the Standard of Care when prescribed with a medication for their Major depression disorder, versus a group of patients that used the Predictix Antidepressant tool when prescribed with a medication for their Major depression disorder by their treating physician. Success will be measured by the number (proportion) of responders per group.

Study Overview

• Status: Unknown
• Conditions: Major Depressive Disorder
• Intervention / Treatment: Device: Predictix Antidepressant

Detailed Description

The study will be comprised of two arms:

1. PGT arm - Predictix Antidepressant-guided treatment condition
2. SOC (control) arm - Standard of Care condition Eligible subjects will be assigned to one of the study arms at a 1:1 ratio and will be followed for a period of 12 weeks.

An assigned psychiatric expert will review and approve subject's eligibility prior to entrance to the study, as well as, the medication/s prescribed based on the Predictix report prior to treatment start.

During the 12 weeks of follow up , data will be collected at the following timepoints: Screening, Baseline (start of treatment) and at 4, 8 and 12 weeks.

Visits will include the completion of several questionnaires designed to answer the study objectives, either as self-reported by the patients and/ or by the physician.

Depression scores by the Quick Inventory of Depressive Symptomatology (QIDS 16) questionnaire and evaluation of all safety related endpoints will be analyzed following the completion of the 12 weeks visit procedures. In case of a change in treatment, as per the treating physician's decision, a new 12 weeks cycle of data collection will start. Two independent cycles are permitted per patient.

In addition, retrospective (6 months prior to enrollment) and long-term follow up period data (12 months post enrollment) will be analyzed, in order to evaluate the device use effect on patients care outcomes in terms of economic burden and Social impact, on patients, employers, the health care system and payers.

The analysis will be based on both the work productivity and activity impairment questionnaire and the patient's electronic medical data record.

• Study Type: Interventional
• Enrollment (Anticipated): 220
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Dekel Taliaz, Dr.; Phone Number: +972-77- 3352506; Email: dekel@taliazhealth.com

Study Locations

• Israel
  • Tel Aviv, Israel
    • Recruiting
    • Maccabi Healthcare Services
    • Contact: Barak Nada, Mr.; Phone Number: 972747569300; Email: nada_b@mac.org.il
    • Principal Investigator: Orit Stein, Dr.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male and female at the age of 18 - 75 years old at time of screening.
• MDD diagnosis per DSM V at screening visit or prior to screening visit.
• Rule out other causes of depressive symptoms other than MDD.
• Ability to read, understand and sign an informed consent document
• Female subjects at reproductive age that are tested negative for pregnancy
• Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods during the whole study duration

Exclusion Criteria:

• Patient is currently on an antidepressant treatment.
• Patient is diagnosed with other major psychopathologies (i.e. schizophrenia, bipolar disorder, psychotic depression, geriatric depression).
• requires antipsychotic medication or mood stabilizers.
• Patient is at substantial suicidal risk as judged by the treating physician
• Patient has attempted suicide in the past year.
• Patient has any current unstable medical condition or surgical illness.
• Patient has history of seizure or convulsions.
• Patient has history of drug abuse or alcoholism in the last 6 months.
• Inadequate communication with the patient.
• Patient has participated in another clinical study in the last 30 days preceding this study.
• In the investigator's judgement, patient is not able to provide written informed consent and follow protocol requirements.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PGT arm; Predictix Antidepressant-guided treatment condition	Device: Predictix Antidepressant; Predictix Antidepressant guided treatment
No Intervention: soc arm; Standard of Care condition

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Response rate in the PGT and SOC groups	Overall Response rate with and without the use of the Predictix Antidepressant software tool. Response is measures as at least 45% reduction in symptoms severity, measured by the Quick Inventory of Depressive Symptomatology (QIDS 16)	12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in Quick Inventory of Depressive Symptomatology( QIDS 16) self reported score	Change in total score of the self reported questionnaire. Total score range is 0-48	12 weeks
Usability and satisfaction of the Predictix tool	review of completed questionnaires by the treating family physician/general practitioner and psychiatric expert. Total score rate in 12-84. (higher value represent better outcome)	12 weeks
Economic burden* and social impact on patients, employers, the health system and payers	Based on the analysis of the patients' electronic medical data record retrospectively (6 months prior to enrollment) and following a long-term follow up period	12 month

Collaborators and Investigators

• Sponsor: Taliaz Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2018
• Primary Completion (Anticipated): December 1, 2020
• Study Completion (Anticipated): December 1, 2020

Study Registration Dates

• First Submitted: July 14, 2019
• First Submitted That Met QC Criteria: July 21, 2019
• First Posted (Actual): July 24, 2019

Study Record Updates

• Last Update Posted (Actual): July 24, 2019
• Last Update Submitted That Met QC Criteria: July 21, 2019
• Last Verified: July 1, 2019

More Information

Terms related to this study

• Keywords: MDD
• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Mood Disorders; Depression; Depressive Disorder; Depressive Disorder, Major; Psychotropic Drugs; Antidepressive Agents
• Other Study ID Numbers: CL-02-PRT-02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No